Session

IBD (Posters)

LIVE VACCINES IN CHILDREN EXPOSED TO BIOLOGICAL AGENTS FOR IBD IN UTERO AND/OR DURING BREASTFEEDING: ARE THEY SAFE? RESULTS FROM THE DUMBO REGISTRY OF GETECCU
LIVE VACCINES IN CHILDREN EXPOSED TO BIOLOGICAL AGENTS FOR IBD IN UTERO AND/OR DURING BREASTFEEDING: ARE THEY SAFE? RESULTS FROM THE DUMBO REGISTRY OF GETECCU

EFFICACY AND SAFETY OF USTEKINUMAB IN ASIAN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A SUBPOPULATION ANALYSIS OF UNIFI LONG-TERM EXTENSION THROUGH 3 YEARS
EFFICACY AND SAFETY OF USTEKINUMAB IN ASIAN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A SUBPOPULATION ANALYSIS OF UNIFI LONG-TERM EXTENSION THROUGH 3 YEARS

C-REACTIVE PROTEIN/ALBUMIN RATIO (CAR) AS A MARKER FOR DETECTING ACUTE SEVERE ULCERATIVE COLITIS IN EGYPTIAN PATIENTS
C-REACTIVE PROTEIN/ALBUMIN RATIO (CAR) AS A MARKER FOR DETECTING ACUTE SEVERE ULCERATIVE COLITIS IN EGYPTIAN PATIENTS

THE EFFECT OF INDUCTION THERAPY WITH INFLIXIMAB OR VEDOLIZUMAB ON HEPCIDIN AND IRON STATUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
THE EFFECT OF INDUCTION THERAPY WITH INFLIXIMAB OR VEDOLIZUMAB ON HEPCIDIN AND IRON STATUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

PREVALENCE OF IRON DEFICIENCY AND ANAEMIA IN THE OUTPATIENT INFLAMMATORY BOWEL DISEASE POPULATION: A DUTCH NATIONAL CROSS-SECTIONAL STUDY
PREVALENCE OF IRON DEFICIENCY AND ANAEMIA IN THE OUTPATIENT INFLAMMATORY BOWEL DISEASE POPULATION: A DUTCH NATIONAL CROSS-SECTIONAL STUDY

PLASMA FATTY ACID BINDING PROTEIN 2, INTERLEUKIN-10 AND LIPOPOLYSACCHARIDES AS BIOMARKERS FOR MICROSCOPIC COLITIS
PLASMA FATTY ACID BINDING PROTEIN 2, INTERLEUKIN-10 AND LIPOPOLYSACCHARIDES AS BIOMARKERS FOR MICROSCOPIC COLITIS

INFLUENCE OF CELIAC DISEASE ON THE COURSE OF INFLAMMATORY BOWEL DISEASE
INFLUENCE OF CELIAC DISEASE ON THE COURSE OF INFLAMMATORY BOWEL DISEASE

CONTRAST-ENHANCED INTESTINAL ULTRASOUND: TIME TO REFRESH THE NON-INVASIVE MONITORING IN CROHN’S DISEASE
CONTRAST-ENHANCED INTESTINAL ULTRASOUND: TIME TO REFRESH THE NON-INVASIVE MONITORING IN CROHN’S DISEASE

SAFETY OF TOFACITINIB IN THE TREATMENT OF ULCERATIVE COLITIS:
SAFETY OF TOFACITINIB IN THE TREATMENT OF ULCERATIVE COLITIS:

PROGNOSTIC MODEL FOR THE OCCURRENCE OF A COMPOSITE OUTCOME IN CROHN’S DISEASE PATIENTS UNDER INFLIXIMAB MAINTENANCE THERAPY
PROGNOSTIC MODEL FOR THE OCCURRENCE OF A COMPOSITE OUTCOME IN CROHN’S DISEASE PATIENTS UNDER INFLIXIMAB MAINTENANCE THERAPY

SWITCH FROM INTRAVENOUS TO SUB-CUTANEOUS INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE: WHICH CONSEQUENCES FROM A PHARMACOKINETIC PERSPECTIVE?
SWITCH FROM INTRAVENOUS TO SUB-CUTANEOUS INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE: WHICH CONSEQUENCES FROM A PHARMACOKINETIC PERSPECTIVE?

QINGDAI (QD) FOR PATIENTS WITH ACTIVE ULCERATIVE COLITIS: A RETROSPECTIVE ISRAELI NATIONAL EXPERIENCE
QINGDAI (QD) FOR PATIENTS WITH ACTIVE ULCERATIVE COLITIS: A RETROSPECTIVE ISRAELI NATIONAL EXPERIENCE

LONG-TERM TREATMENT PERSISTENCE WITH INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A REAL-WORLD STUDY
LONG-TERM TREATMENT PERSISTENCE WITH INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A REAL-WORLD STUDY

USTEKINUMAB DRUG EXPOSURE IS NOT LINKED TO CHANGES IN BOWEL WALL THICKNESS, BUT DOES ASSOCIATE WITH TRANSMURAL REMISSION IN CROHN’S DISEASE
USTEKINUMAB DRUG EXPOSURE IS NOT LINKED TO CHANGES IN BOWEL WALL THICKNESS, BUT DOES ASSOCIATE WITH TRANSMURAL REMISSION IN CROHN’S DISEASE

EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING 16 WEEKS’ EXTENDED INDUCTION TREATMENT FOLLOWED BY 52 WEEKS’ MAINTENANCE TREATMENT IN THE U-ACHIEVE/U-ACCOMPLISH TRIALS
EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING 16 WEEKS’ EXTENDED INDUCTION TREATMENT FOLLOWED BY 52 WEEKS’ MAINTENANCE TREATMENT IN THE U-ACHIEVE/U-ACCOMPLISH TRIALS

USTEKINUMAB PERSISTENCE IN THE TREATMENT OF CROHN’S DISEASE, FISTULIZING CROHN’S DISEASE AND ULCERATIVE COLITIS
USTEKINUMAB PERSISTENCE IN THE TREATMENT OF CROHN’S DISEASE, FISTULIZING CROHN’S DISEASE AND ULCERATIVE COLITIS

COMPARATIVE ANALYSIS OF ORIGINATOR VERSUS BIOSIMILAR COUNTERPARTS WHEN TREATING ULCERATIVE COLITIS
COMPARATIVE ANALYSIS OF ORIGINATOR VERSUS BIOSIMILAR COUNTERPARTS WHEN TREATING ULCERATIVE COLITIS

AN OPTIMIZATION OF INFLAMMATORY BOWEL DISEASES DIAGNOSIS USING AN ARTIFICIAL INTELLIGENCE
AN OPTIMIZATION OF INFLAMMATORY BOWEL DISEASES DIAGNOSIS USING AN ARTIFICIAL INTELLIGENCE

CHARACTERISTICS AND IMPACT OF ANXIETY AND DEPRESSION TRAJECTORIES IN INFLAMMATORY BOWEL DISEASE
CHARACTERISTICS AND IMPACT OF ANXIETY AND DEPRESSION TRAJECTORIES IN INFLAMMATORY BOWEL DISEASE

FACTORS ASSOCIATED WITH RESECTION IN ISOLATED ILEAL CROHN’S DISEASE IN AN ASIAN COHORT
FACTORS ASSOCIATED WITH RESECTION IN ISOLATED ILEAL CROHN’S DISEASE IN AN ASIAN COHORT

Item 161 - 180 / 612
1 2 3 4 5 6 7 8
9
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31